Related Experiment Videos
Antibiotic resistance versus small molecules, the chemical evolution
1Microcide Pharmaceuticals, Inc., Mountain View, California 94043, USA. vingjlee@microcide.com
Medicinal Research Reviews
|November 11, 1999
Summary
Researchers developed novel antibiotics to combat rising bacterial resistance. One approach enhances cephalosporins against methicillin-resistant Staphylococcus aureus (MRSA), while another explores uridyl peptide analogs targeting bacterial translocase.
Area of Science:
- Medicinal Chemistry
- Microbiology
- Drug Discovery
Background:
- Increasing bacterial resistance poses a significant global health threat.
- Novel strategies are urgently needed to develop effective antibacterial agents.
- Existing antibiotic classes face challenges due to resistance mechanisms.
Purpose of the Study:
- To discover and develop new antibacterial compounds targeting resistant bacterial strains.
- To investigate two distinct approaches: modifying cephalosporins for anti-MRSA activity and exploring uridyl peptide analogs.
- To optimize lead compounds for improved potency, stability, and spectrum of activity.
Main Methods:
- Cephalosporin modification focused on enhancing affinity for PBP2a, the key protein in MRSA resistance.
- Total synthesis of uridyl peptide analogs, including exploration of structure-activity relationships (SAR).
- Stereochemical determination of key moieties (DABA and 4'-substituent) using degradation and synthesis.
Main Results:
- Development of novel cephalosporin compounds with potential anti-MRSA activity, including MC-02,479 (RWJ-54428) for preclinical evaluation.
- Successful total synthesis of diverse uridyl peptide analogs, revealing that 4'-exoenamidofuranosyl moiety hydrogenation retains biological activity.
- Elucidation of stereochemistry crucial for understanding the SAR of uridyl peptide antibiotics.
Conclusions:
- Two promising avenues for developing new antibiotics against resistant bacteria have been identified.
- Optimized cephalosporins show potential for treating MRSA infections.
- Synthetically accessible uridyl peptide analogs offer insights into new antibacterial therapies.